Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Nurix Therapeutics (NRIX) EBITDA Margin: 2019-2025

Historic EBITDA Margin for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to -1,157.65%.

  • Nurix Therapeutics' EBITDA Margin fell 72382.00% to -1,157.65% in Q3 2025 from the same period last year, while for Aug 2025 it was -319.32%, marking a year-over-year increase of 2398.00%. This contributed to the annual value of -390.52% for FY2024, which is 18911.00% down from last year.
  • Nurix Therapeutics' EBITDA Margin amounted to -1,157.65% in Q3 2025, which was down 955.45% from -109.68% recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' EBITDA Margin registered a high of -87.25% during Q2 2023, and its lowest value of -1,157.65% during Q3 2025.
  • In the last 3 years, Nurix Therapeutics' EBITDA Margin had a median value of -338.60% in 2023 and averaged -376.75%.
  • Per our database at Business Quant, Nurix Therapeutics' EBITDA Margin skyrocketed by 41,877bps in 2023 and then plummeted by 72,382bps in 2025.
  • Quarterly analysis of 5 years shows Nurix Therapeutics' EBITDA Margin stood at -513.16% in 2021, then tumbled by 20,467bps to -717.82% in 2022, then soared by 41,877bps to -299.06% in 2023, then tumbled by 18,767bps to -486.73% in 2024, then tumbled by 72,382bps to -1,157.65% in 2025.
  • Its EBITDA Margin was -1,157.65% in Q3 2025, compared to -109.68% in Q2 2025 and -340.67% in Q1 2025.